Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

For MedTech founders and regulatory directors, “first patient in” is not a single milestone—it is the outcome of dozens of parallel workstreams that must converge at the right time. Brazil has become an increasingly attractive environment for early-stage studies because the country’s regulatory pathway has defined review timelines for parts of the process, including a 90-business-day window for ANVISA’s analysis of key clinical trial petitions as described by the U.S. NIH’s ClinRegs Brazil overview.

But a fast clock on paper does not automatically translate into a fast activation in practice. Sponsors still lose weeks when ethics submissions, ANVISA dossiers, import readiness, and site enablement are treated as sequential tasks rather than an integrated program. This article provides a practical first-in-human (FIH) activation timeline for Brazil—designed for medical devices and combination products—so teams can predict the critical path, reduce avoidable rework, and protect study quality.

Why Brazil is different for early-stage activation

Brazil’s clinical research oversight operates as a dual system. On the regulatory side, ANVISA is responsible for clinical trial oversight, approvals, and inspections. On the ethics side, institutional Research Ethics Committees (CEPs) and the National Research Ethics Commission (CONEP) safeguard participant rights and may be required for certain studies, including some with foreign sponsorship. ClinRegs notes that clinical trials may only begin after both ethics and ANVISA approvals are in place, and that sponsors can submit in parallel rather than waiting for one decision before starting the other.

For FIH programs, the key operational insight is that “parallel” only works if your team pre-builds the dossier and operational backbone in a way that prevents late-stage gaps. That means aligning protocol, investigator’s brochure (or device equivalent), risk management, investigational product logistics, and site readiness into one activation plan.

A practical FIH activation timeline (week-by-week)

The timeline below is a planning template. Your specific path will vary based on device risk class, whether the product is a device-only investigation or a drug-device combination, whether import is required, and whether CONEP review applies. Still, most FIH teams benefit from managing the activation plan as six overlapping phases.

Phase 1 (Weeks 0–2): Activation blueprint and dossier alignment

• Define the activation goal: first patient in, first-in-country, or first site activated—then translate it into a dated plan with owners.
• Freeze core scientific documents: protocol, statistical approach (if applicable), investigator brochure/device technical file summary, informed consent draft, and safety monitoring plan.
• Pre-brief sites: confirm investigator interest, feasibility, patient pool, and required imaging/lab capabilities.
• Map the import path: determine whether investigational product import will be needed, what documents are required, and when to initiate customs planning.

Common pitfall: teams treat feasibility as “business development,” then discover late that the site cannot execute key assessments. For FIH studies, feasibility should be treated as a protocol risk-control activity.

Phase 2 (Weeks 2–4): Parallel submission readiness (ethics + ANVISA)

ClinRegs indicates that clinical trial applications can be submitted in parallel in Brazil. Use that advantage. Your objective in this phase is not merely to “submit,” but to submit dossiers that survive the first pass without avoidable queries.

• Ethics package readiness: ensure Portuguese-language materials, recruitment approach, participant protections, investigator CVs, and site documentation are complete.
• Regulatory package readiness: align device description, risk analysis, prior testing, clinical rationale, and monitoring approach into an internally consistent narrative.
• Operational readiness: contract templates, budget assumptions, data capture approach, and vendor onboarding plan.

Tip: run an internal “approval simulation” meeting before submission. Ask: if the reviewer questions the risk–benefit logic, do we have a clear answer embedded in the dossier?

Phase 3 (Weeks 4–10): Review window management and rapid-response loop

ClinRegs describes a 90-business-day timeframe for ANVISA’s analysis of key clinical trial dossiers, with defined sponsor response windows when additional information is requested. Even with set timelines, the sponsor’s responsiveness and document discipline often determine whether the review stays on track.

• Stand up a “question-response” war room: pre-assign technical owners (clinical, quality, regulatory, biostatistics, logistics) so questions can be addressed within days, not weeks.
• Maintain a single source of truth: track every submitted document version and every response in a controlled repository.
• Keep sites warm: train coordinators, initiate essential vendor qualification, and prepare for SIV scheduling so you can start immediately after approvals.

Common pitfall: teams wait for approval before planning site initiation, then lose 2–4 weeks to avoidable scheduling and vendor delays.

Phase 4 (Weeks 8–12): Import and investigational product readiness

FIH programs fail more often from logistics than from science. If you need to import devices, kits, or ancillary supplies, design the import process as a parallel track, not an afterthought.

• Confirm labeling and packaging requirements: ensure your investigational labeling supports clinical-use workflows and aligns with the protocol.
• Build a customs-ready document pack: commercial invoice equivalents, certificates, and product descriptions that minimize ambiguity.
• Create a buffer strategy: hold contingency inventory or stage supplies locally when feasible.

Tip: for FIH devices, plan at least one “mock shipment” exercise or logistics rehearsal, even if it’s document-only. The point is to find gaps while time remains.

Phase 5 (Weeks 10–14): Site initiation and first patient in

• Run targeted SIVs: prioritize protocol-critical procedures, safety reporting, and data integrity steps.
• Operationalize screening: define screening triggers, referral pathways, and investigator decision trees.
• Monitor early execution: the first 1–3 patients usually reveal whether your trial design is workable in the real world.

Common pitfall: launching without clear screening criteria and without real-time visibility into early deviations. For FIH, early deviations often signal that the trial design needs operational adjustments.

Phase 6 (Weeks 14+): Stabilize, scale sites, and protect data quality

• Scale site network deliberately: expand only after the first site demonstrates protocol adherence and predictable enrollment.
• Harden the safety loop: ensure rapid reporting, investigator training, and sponsor review cadence.
• Maintain audit readiness: document control and deviation management are not optional; they are how you preserve the value of your data for future submissions.

Checklist: What to pre-build before you submit

• Protocol + operational workflow map (how each visit is executed at the site)
• Device/technology summary that is consistent across regulatory, ethics, and site materials
• Risk management narrative that ties hazards to mitigations and monitoring
• Import-readiness pack with clear product descriptors and shipping plan
• Vendor onboarding plan (labs, imaging, data capture, logistics) aligned to activation dates
• Response war room with named owners and draft response templates

FAQ

1) Can we submit to ethics and ANVISA at the same time in Brazil?

Yes. ClinRegs indicates that clinical trial applications can be submitted in parallel, but trials should not start until both approvals are in place. The operational value is in reducing idle time by building parallel readiness workstreams.

2) What typically delays first-in-human activation the most?

In many FIH programs, delays come from late dossier inconsistencies, slow responses to reviewer questions, and underestimated import and site-startup tasks. Treat activation as a program with a critical path rather than a compliance checklist.

3) How do we protect data quality while moving fast?

Move fast by reducing rework—not by cutting corners. Standardize document control, train sites on protocol-critical steps, and implement real-time deviation monitoring so you can correct execution issues early.

Educational content only. Sponsors should consult qualified regulatory and clinical research professionals for study-specific planning.